

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bolzon Bradley J PhD</u>  (Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Black Diamond Therapeutics, Inc.</u> [ BDTX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 11/27/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/27/2020		J <sup>(1)</sup>		394,000	D	\$0.00	3,947,941	I	See Footnote <sup>(2)</sup>
Common Stock	11/27/2020		J <sup>(3)</sup>		7,880	A	\$0.00	7,880	I	See Footnote <sup>(4)</sup>
Common Stock	11/27/2020		J <sup>(5)</sup>		7,880	D	\$0.00	0	I	See Footnote <sup>(4)</sup>
Common Stock	11/27/2020		J <sup>(6)</sup>		6,797	A	\$0.00	6,797	I	See Footnote <sup>(7)</sup>
Common Stock	11/27/2020		J <sup>(8)</sup>		6,797	D	\$0.00	0	I	See Footnote <sup>(7)</sup>
Common Stock	11/27/2020		J <sup>(9)</sup>		2,256	A	\$0.00	21,825	D	
Common Stock	11/30/2020		S <sup>(10)</sup>		10,193	D	\$33.1286 <sup>(11)</sup>	874,299	I	See Footnote <sup>(12)</sup>
Common Stock	11/30/2020		S <sup>(10)</sup>		200	D	\$34.1646 <sup>(13)</sup>	874,099	I	See Footnote <sup>(12)</sup>
Common Stock	11/30/2020		J <sup>(14)</sup>		31,175	D	\$0.00	842,924	I	See Footnote <sup>(12)</sup>
Common Stock	11/30/2020		J <sup>(15)</sup>		467	A	\$0.00	467	I	See Footnote <sup>(16)</sup>
Common Stock	11/30/2020		J <sup>(17)</sup>		467	D	\$0.00	0	I	See Footnote <sup>(16)</sup>
Common Stock	11/30/2020		J <sup>(18)</sup>		463	A	\$0.00	463	I	See Footnote <sup>(19)</sup>
Common Stock	11/30/2020		J <sup>(20)</sup>		463	D	\$0.00	0	I	See Footnote <sup>(19)</sup>
Common Stock	11/30/2020		J <sup>(21)</sup>		15	A	\$0.00	21,840	D	
Common Stock								1,277,541	I	See Footnote <sup>(22)</sup>
Common Stock								380,942	I	See Footnote <sup>(23)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

--

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Underlying Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
--	--	--------------------------------------	--------------------------------	--	--	---	--	--	---	--

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Underlying Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
--	--	--------------------------------------	--	--------------------------------	--	--	---	--	--	---	--

**Explanation of Responses:**

1. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VC VI") to its partners, pursuant to a Rule 10b5-1 trading plan adopted by Versant VC VI.

2. Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

3. Represents a change in the form of ownership of Versant Ventures VI GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VI.

4. Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

5. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP to its partners.

6. Represents a change in the form of ownership of Versant Ventures VI GP-GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP.

7. Shares held by Versant Ventures VI GP-GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

8. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP-GP to its members.

9. Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP-GP.

10. The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Vantage I, L.P. ("Versant Vantage I").

11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.00 to \$33.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11) to this Form 4.

12. Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.77 to \$34.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (13) to this Form 4.

14. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("Versant Vantage I") to its partners, pursuant to a Rule 10b5-1 trading plan.

15. Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I.

16. Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

17. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners.

18. Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP.

19. Shares held by Versant Vantage I GP-GP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

20. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members.

21. Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP-GP.

22. Shares held by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. The Reporting Person may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

23. Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

**Remarks:**

/s/ Robin L. Praeger, Attorney  
- in - fact for Bradley J. Bolzon, PhD.      12/01/2020  
 \*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.